T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant

P. Comoli, S. Basso, M. Labirio, F. Baldanti, R. Maccario, F. Locatelli

Research output: Contribution to journalArticle

Abstract

Epstein-Barr virus (EBV)-associated post-transplant lymphoproliferative disease (PTLD) and adenovirus (AdV)-related pathologies are life-threatening complications of immunosuppression in recipients of hematopoietic stem cell transplantation (HSCT). In certain cohorts (unrelated and haploidentical donor HSCT, T-cell-depleted allograft), the risk of developing these complications is higher. Here we describe the impact of T cell therapy, within programs of specific routine surveillance and preemptive treatment, on the course of EBV infection, and development of related disease, in pediatric recipients of T-cell-depleted, HLA-haploidentical HSCT. Future prospectives include the transfer of this technology to treat AdV-related complications following HSCT.

Original languageEnglish
Pages (from-to)68-70
Number of pages3
JournalBlood cells, molecules & diseases
Volume40
Issue number1
DOIs
Publication statusPublished - Jan 2008

Keywords

  • Adenovirus
  • Adoptive cellular therapy
  • Epstein-Barr virus
  • Hemopoietic stem cell transplantation
  • Post-transplant lymphoproliferative disease
  • Rituximab

ASJC Scopus subject areas

  • Molecular Biology
  • Molecular Medicine
  • Hematology

Fingerprint Dive into the research topics of 'T cell therapy of Epstein-Barr virus and adenovirus infections after hemopoietic stem cell transplant'. Together they form a unique fingerprint.

  • Cite this